Catalyst Pharmaceutical Partners Inc buy Savour
Start price
13.12.20
/
50%
€3.06
Target price
13.12.21
-
Performance (%)
1.50%
End price
11.03.21
€3.10
Summary
This prediction ended on 11.03.21 with a price of €3.10. The BUY prediction by Savour finished with a performance of 1.50%. Savour has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| Catalyst Pharmaceutical Partners Inc | -5.782% | -5.782% | -4.739% | 260.660% |
| iShares Core DAX® | 2.594% | -1.861% | 13.242% | 16.867% |
| iShares Nasdaq 100 | 3.553% | -2.064% | 38.293% | 45.898% |
| iShares Nikkei 225® | 0.687% | -8.704% | 17.510% | 2.760% |
| iShares S&P 500 | 2.209% | -1.988% | 27.632% | 42.955% |
According to Savour what are the pros and cons of Catalyst Pharmaceutical Partners Inc for the foreseeable future?
Pros
Could be worthwhile Investment >10% per year
Revenue growth >5% per year expected
Cons
Comments by Savour for this prediction
In the thread Catalyst Pharmaceutical Partners Inc diskutieren
Buy Catalyst Pharmaceutical Partners Inc